PerMed Biosciences Announces Financial and Business Information Due to Securities Trading Alert Threshold on Centralized Market
NQ Score
77/100
N1 Content Completeness
9
AI Summary (NQ-processed)
PerMed Biosciences discloses financial information as its securities met the Taiwan Stock Exchange's alert threshold for trading. Monthly revenue rose 18.76% YoY, but quarterly revenue dropped 46.68% and losses widened.
AI Analysis
Frequently Asked Questions
- Q: What is PerMed Biosciences' latest monthly revenue?
- A: Revenue for May 2026 was NT$2.69 billion, up 18.76% YoY.
- Q: What was PerMed's quarterly net loss?
- A: Pre-tax net loss for Q1 2026 was NT$871.74 million, down 12.83% from last year.
- Q: Will there be a major information briefing?
- A: No, no briefing is scheduled as no material events under TWSE rules occurred.